Decision on Covaxin nod likely in 4-6 weeks: WHO

Prequalification necessary to supply vaccines to global facilitiesor Target was to have at least 10% of world fully vaccinated by Sept., says Chief Scientist Soumya Swaminathan

July 09, 2021 06:09 pm | Updated 06:09 pm IST - NEW DELHI

A health worker shows a vial of (SARS-CoV-2) Covaxin vaccine. File

A health worker shows a vial of (SARS-CoV-2) Covaxin vaccine. File

The World Health Organisation (WHO) is likely to take a decision on including Bharat Biotech’s Covaxin in its list of vaccines approved for Emergency Use, within four to six weeks, Soumya Swaminathan, Chief Scientist, WHO said at a webinar organised by the Centre for Science and Environment (CSE).

A WHO prequalification, or EUL, is necessary for a vaccine company to supply vaccines to global facilities such as COVAX or international procurement. So far eight vaccines have got an EUL from the WHO.

“It is mandatory to supply a complete dossier listing safety, efficacy and manufacturing conditions of the vaccine to the WHO. I understand that Bharat Biotech is in this process and I think a decision on their case is likely in the next four to six weeks,” said Swaminathan.

The EUL assesses the quality, safety and efficacy of COVID-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements. The assessment is performed by the product evaluation group, composed by regulatory experts from around the world and a Technical Advisory Group (TAG), in charge of performing the risk-benefit assessment for an independent recommendation on whether a vaccine can be listed for emergency use and, if so, under which conditions, the WHO says.

In late May, Bharat Biotech said it has submitted “90% of the data” required for the pre-qualification process. Last Saturday, the firm publicised its long-awaited phase-3 trial efficacy data, via an non-peer-reviewed pre-print publication, reporting an overall 77.8% efficacy against symptomatic COVID-19 based on analysis involving 25,800 volunteers.

The two-dose vaccine was also 93.4% effective against severe disease and 63% protective against asymptomatic COVID. Moreover, it was 65% protective against the Delta variant. of the coronavirus, the most widespread in India and linked to a rising number of cases in Europe as well as the United States.

Bharat Biotech didn't respond to a query from The Hindu on Dr. Swaminathan's statement.

At Friday’s seminar, Dr. Swaminathan said that it was “frustrating” that countries were contemplating and testing booster doses for themselves when large parts of the world, especially Africa, hadn’t yet got vaccinated.

The target was to have at least 10% of the world fully vaccinated by September and 40% by December. She said that it was unlikely that the world would be sufficiently protected at least until the next year and a half and ‘herd immunity’, or when substantial fraction of people was protected by antibodies, was only likely when 80% had been vaccinated.

So far only 5% of Indians have been fully vaccinated and only 21.8% have got at least one dose of the vaccine.

Top News Today


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.